Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: Beyond persistence

BMC Health Services Research

Volumn 7, Issue , 2007, Pages

  Menckeberg, Tanja T ^a,b   Belitser, Svetlana V ^a   Bouvy, Marcel L ^a,b   Bracke, Madelon ^a   Lammers, Jan Willem J ^c   Raaijmakers, Jan A M ^a   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; ARTICLE; BEHAVIOR; CHRONIC DISEASE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NETHERLANDS; PRESCRIPTION; PROBABILITY; DRUG SELF ADMINISTRATION; PATIENT CARE; PATIENT COMPLIANCE; STATISTICS;

CHRONIC DISEASE; CONTINUITY OF PATIENT CARE; HUMANS; MARKOV CHAINS; NETHERLANDS; PATIENT COMPLIANCE; PROBABILITY; SELF ADMINISTRATION;

EID: 34548315758     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-7-106     Document Type: Article

References (28)

1. Diet, nutrition and the prevention of chronic diseases. Geneva, World Health Organisation 2003 150
2. WHO strategy for prevention and control of chronic respiratory diseases. Geneva, World Health Organisation 2002
3. Global Initiative for Asthma: Global strategy for asthma management and prevention. GINA, Bethesda, MD, National Institutes of Health, National Heart Lung and Blood Institute 2005
4. Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review. H Powell PG Gibson, Thorax 2004 59 1041 1045 10.1136/thx.2004.023754 15563702
5. Once-daily inhaled corticosteroids for the treatment of asthma. LP Boulet, Curr Opin Pulm Med 2004 10 15 21 10.1097/00063198-200401000-00004 14749601
6. Adherence to medication. L Osterberg T Blaschke, N Engl J Med 2005 353 487 497 10.1056/NEJMra050100 16079372
7. Compliance in asthma. GM Cochrane R Horne P Chanez, Respir Med 1999 93 763 769 10.1016/S0954-6111(99)90260-3 10603624
8. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. MG Cochrane MV Bala KE Downs J Mauskopf RH Ben-Joseph, Chest 2000 117 542 550 10.1378/chest.117.2.542 10669701
9. Persistence with inhaled corticosteroid therapy in daily practice. NS Breekveldt-Postma CM Gerrits JW Lammers JA Raaijmakers RM Herings, Respir Med 2004 98 752 759 10.1016/j.rmed.2004.01.014 15303640
10. Issues in patient compliance: the search for therapeutic sufficiency. P Rudd S Ahmed V Zachary C Barton D Bonduelle, Cardiology 1992 80 Suppl 1 2 10 1600536
11. Pill count measures of compliance in a drug trial: variability and suitability. P Rudd RL Byyny V Zachary ME LoVerde WD Mitchell C Titus G Marshall, Am J Hypertens 1988 1 309 312 3291897
12. The assessment of refill compliance using pharmacy records: methods, validity, and applications. JF Steiner AV Prochazka, J Clin Epidemiol 1997 50 105 116 10.1016/S0895-4356(96)00268-5 9048695
13. Estimating medication persistency using administrative claims data. R Sikka F Xia RE Aubert, Am J Manag Care 2005 11 449 457 16044982
14. Inhaled steroids and the risk of hospitalization for asthma. JG Donahue ST Weiss JM Livingston MA Goetsch DK Greineder R Platt, Jama 1997 277 887 891 10.1001/jama.277.11.887 9062326
15. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. S Suissa P Ernst A Kezouh, Thorax 2002 57 880 884 10.1136/thorax.57.10.880 12324675
16. Respiratory medications and risk of asthma death. SF Lanes LA Garcia Rodriguez C Huerta, Thorax 2002 57 683 686 10.1136/thorax.57.8.683 12149527
17. Pharmacoutilization of antihypertensive drugs: a model of analysis. E Degli Esposti A Sturani L Degli Esposti PL Macini P Falasca G Valpiani S Buda, Int J Clin Pharmacol Ther 2001 39 251 258 11430633
18. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. BM Psaty TD Koepsell EH Wagner JP LoGerfo TS Inui, Jama 1990 263 1653 1657 10.1001/jama.263.12.1653 1968518
19. Measuring disease occurrence and causal effects. KJ Rothman, Epidemiology An introduction USA, Oxford University Press 2002 Chapter 3 24 56
20. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. RM Herings A Bakker BH Stricker G Nap, J Epidemiol Community Health 1992 46 136 140 1349911
21. PHARMO: A record linkage system for postmarketing surveillance of prescription drugs in the Netherlands. RM Herings, Utrecht Institute for Pharmaceutical Sciences Utrecht, Utrecht University 1993
22. An introduction to the bootstrap. B Efron RJ Tibshirani, New York, Chapmann & Hall 1993
23. Evaluating medication effects outside of clinical trials: new-user designs. WA Ray, Am J Epidemiol 2003 158 915 920 10.1093/aje/kwg231 14585769
24. Rate and determinants of 10-year persistence with antihypertensive drugs. BL Van Wijk OH Klungel ER Heerdink A de Boer, J Hypertens 2005 23 2101 2107 10.1097/01.hjh.0000187261.40190.2e 16208154
25. Long term persistence with statin treatment in daily medical practice. AK Mantel-Teeuwisse WG Goettsch OH Klungel A de Boer RM Herings, Heart 2004 90 1065 1066 10.1136/hrt.2003.026187 15310708
26. Oral antithrombotic use among myocardial infarction patients. ME van der Elst N Cisneros-Gonzalez CJ de Blaey H Buurma A de Boer, Ann Pharmacother 2003 37 143 146 10.1345/aph.1C038 12503950
27. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. ML Bouvy ER Heerdink HG Leufkens AW Hoes, Eur J Heart Fail 2003 5 195 200 10.1016/S1388-9842(02)00256-8 12644012
28. Pharmacoepidemiological modelling: Markov models of antibiotic use in patients with diabetes. HG Leufkens, Neth J Med 2002 60 78 82 12430594